Department of Rheumatology and Immunology

Education

http://intranet.pote.hu/OKTATAS/diatar/immunology

Physical examination of the musculoskeletal system (the GALS examination)

Watch the video: http://www.eular.org/video/Video_Learning_Tools_GALS.cfm

Download the video: www.eular.ch/edu_training_dvd.cfm



1.    Czirják L, Surányi P, Dankó K, Szegedi Gy. T lymphocyte subpopulations in progressive systemic sclerosis defined by monoclonal antibodies. Acta Med Hung 1985; 42: 129 132.

2.    Czirják L, Dankó K, Zeher M, Szegedi Gy. Lymphocyte response to mitogens and monocyte  mediated suppression of lymphocyte activation in patients with progressive systemic sclerosis. Ann Immunol Hung 1985; 25: 167 175.

3.    Czirják L, Dankó K, Sonkoly I, Bodolay E, Szegedi Gy. Lymphocyte markers in patients with progressive systemic sclerosis. Acta Med Hung 1985; 42: 109 114.

4.    Sipka S, Ábel Gy, Czirják L, Csongor J, Szegedi Gy, Fachet J. The effect of thrombin activated factor XIII, thrombin and plasmin on the chemiluminescence produced by human neutrophils stimulated by opsonized zymosan (mannosym). Acta Med Hung 1985; 42: 187 191.

5.    Czirják L, Szegedi Gy. Nifedipine treatment for systemic sclerosis (letter) Arthritis Rheum 1986; 29: 1053 1054.

6.    Dankó K, Czirják L, Sipka S, Szegedi Gy. Trends in the research interleukins (IL 1, 2, 3). Ann Immunol Hung 1986; 26: 225 238.

7.    Czirják L, Dankó K, Sipka S, Zeher M, Szegedi, Gy. Polymorphonuclear neutrophil function in systemic sclerosis. Ann Rheum Dis 1987; 46: 302 306.

8.    Surányi P, Czirják L, Szegedi Gy, Damjanovich S. Modulation of T3 antigen in systemic lupus erythematosus (SLE). Acta Med Hung 1987; 44: 311-319.

9.    Czirják L, Szegedi Gy. Benzene exposure and systemic sclerosis (letter). Ann Intern Med 1987; 107: 118.

10.    Czirják L, Dankó K, Schlammadinger J, Surányi P, Tamási L, Szegedi Gy. Progressive systemic sclerosis occurring in patients exposed to chemicals. Int J Dermatol 1987; 26: 374 378.

11.    Sipos A, Czirják L, Lôrincz G, Szegedi, Gy. Studies on anti granulocyte and anti platelet antibodies in patients with systemic sclerosis. Scand J Rheumatol 1988; 17: 43 50.

12.    Czirják L, Dankó K, Zeher M, Szegedi Gy. Function of monocytes in patients with systemic sclerosis. Acta Med Hung 1988; 45: 53 61.

13.    Czirják L, Bokk Á, Csontos Gy, Lôrincz G, Szegedi Gy. A clinical findings in 61 progressive patients with systemic sclerosis. Acta Dermato-Venereol (Stockh.) 1989; 69: 533-536.

14.    Sipos A, Czirják L, Sonkoly I, Szabó G, Sipka S, Boros P, Szegedi Gy. Anti-granulocyte antibodies in immune neutropenia and autoimmune disorders. Acta Paediatrica Hung (suppl) 1989; 29: 97-100.
15.    Sütő G., Garamszegi M., Jávor T., Vincze Á., Mózsik Gy.: Similarities and differences  in the cytoprotection induced by PGI2 and -carotene in experimental ulcers. Acta Physiol. Hung. 1989; 73: 155-158,
16.    Mózsik Gy., Garamszegi M., Sütő G., Vincze Á., Jávor T.: A pharmacological approach to cellular mechanisms of PGI2-induced gastric cytoprotection on ethanol-induced gastric mucosal damage in rats. Acta Physiol. Hung. 1989; 73: 207-211.
17.    Garamszegi M., Jávor T., Sütő G., Vincze Á., Tóth Gy., Mózsik Gy.: Effect of atropine, PGF2, and cimetidine on the -carotene-induced gastric cytoprotection in ethanol-treated rats. Acta Physiol. Hung. 1989; 73: 221-224.
18.    Vincze Á., Garamszegi M., Jávor T., Sütő G., Tigyi A., Tóth Gy., Zsoldos T., Mózsik Gy.: The free radical mechanisms in b-carotene-induced gastric cytoprotection in HCl model. Acta Physiol. Hung. 1989; 73: 351-355.
19.    Mózsik Gy., Garamszegi M., Jávor T., Nagy L., Sütő G., Tóth Gy., Vincze Á.: Cellular energy status of the gastric mucosa and gastric mucosal prevention by vitamin A in indomethacin treated rats. Int. J. Tiss. Reac. 1989; 11: 65-71.
20.    Garamszegi M., Németh A., Patty I., Tárnok F., Mózsik Gy., Vincze Á., Sütő G., Jávor T.: Comparison of the ulcer healing effect of different cytoprotective drugs in gastric ulcer patients. Acta Physiol. Hung. 1990; 75(Suppl.): 127-128. 

21.    Czirják L, Dankó K, Gaulton G. and Stadecker M. J. Thyroid derived epithelial cells acquire alloantigen-presenting capabilities following X-irradiation and class II antigen induction. Eur J Immunol 1990; 20: 2597-2601.

22.    Mózsik Gy., Garamszegi M., Jávor T., Nagy L., Németh A., Sütő G., Vincze Á.: Chemicals (alcohol, NaOH, NaCl, HCl)-induced changes in the gastric mucosal membrane-bound ATP-dependent energy systems. Acta Physiol. Hung. 1990; 75(Suppl.): 217-218.

23.    Mózsik Gy., Király Á., Garamszegi M., Jávor T., Nagy L., Németh A., Sütő G., Vincze Á.: Gastric cytoprotection mediating in SH groups is failed by surgical vagotomy. Acta Physiol. Hung. 1990; 75(Suppl.): 219-220.

24.    Sütő G., Garamszegi M., Jávor T., Nagy L., Németh A., Vincze Á., Mózsik Gy.: Biochemical background of cimetidine-induced gastric mucosal prevention on rats treated with HCl (actions of cytoprotective and antisecretory doses). Acta Physiol. Hung. 1990; 75(Suppl.): 259-260.

25.    Vincze Á., Garamszegi M., Jávor T., Nagy L., Németh A., Sütő G., Mózsik Gy.: Biochemical background of β-carotene-induced gastric cytoprotection in rat treated with HCl. Acta Physiol. Hung. 1990; 75(Suppl.): 293-294.

26.    Mózsik Gy., Garamszegi M., Jávor T., Nagy L., Patty I., Sütő G., Vincze Á.: A biochemical and pharmacological approach to the genesis of ulcer disease II. A model study of stress induced injury to gastric mucosa in rats. Ann. N.Y. Acad. Sci. 1990; 517: 264-281.

27.    Nagy L., Mózsik Gy., Vincze Á., Sütő G., Hunyadi B., Rinfel J., Past T., Jávor T.: Effects of a novel Hungarian antacid containing Al and Mg (TisacidR) on mucosal prostaglandin generation and oxygen free radicals in normal rats. Drug. Exp. Clin. Res. 1990; 16: 197-203.

28.    Hegedüs I. & Czirják L. Septum and posterior wall thickness and disease duration in systemic sclerosis. J Int Med 1991; 229: 383-384.

29.    Czirják L, Schlammadinger J, Szegedi Gy. Anticentromere antibody and Raynaud`s phenomenon. Dermatologica 1991; 183: 55.

30.    Czirják L, Ladányi É, Schlammadinger J, Szegedi, Gy. Signs of systemic disease in localized scleroderma. Arch Dermatol Res 1991; 283: 418.

31.    Vincze Á., Garamszegi M., Jávor T., Sütő G., Tóth Gy., Zsoldos T., Mózsik Gy.: The role of oxygen related free radicals in β-carotene and prostacyclin induced gastric cytoprotection in rats. Eur. J. Gastroenterol. Hepatol. 1991; 3: 175-179.

32.    Mózsik Gy., Sütő G., Garamszegi M., Jávor T., Nagy L., Vincze Á., Zsoldos, T.: Oxygen free radicals and gastric mucosal damage in rats treated with ethanol and HCl. Eur. J. Gastroenterol.. Hepatol. 1991; 3: 757-761. 

33.    Mózsik Gy., Király Á., Garamszegi M., Jávor T., Nagy L., Sütő G., Tóth Gy., Vincze Á.: Failure of prostacyclin, β-carotene, atropine, and cimetidine to produce gastric cyto- and general mucosal protection in surgically vagotomized rats. Life Sci. 1991; 49: 1383-1389. 

34.    Mózsik Gy., Sütő G., Vincze Á.: Correlations between the acute chemical and surgical vagotomy-induced gastric mucosal biochemistry in rats. J. Clin. Gastroenterol. 1992; 14(Suppl.1): S135-S139.

35.    Mózsik Gy., Király Á., Garamszegi M., Jávor T., Nagy L., Németh A., Sütő G., Vincze Á.: Mechanisms of vagal nerve in the gastric mucosal defence: unchanged gastric emptying and increased vascular permeability. J. Clin. Gastroenterol. 1992; 14(Suppl.1): S140-S144.

36.    Mózsik Gy., Király Á., Sütő G., Vincze Á.: ATP breakdown and in the development of gastrointestinal mucosal damage and its prevention in animals and human. (An overview of 25 years ulcer research studies) Acta Physiol. Hung. 1992; 80: 39-80.

37.    Vincze Á., Király Á., Sütő G., Mózsik Gy.: Acute surgical vagotomy (ASV) is an aggressor of gastric mucosa? Acta Physiol. Hung. 1992; 80: 197-205.

38.    Király Á., Sütő G., Vincze Á., Jávor T., Mózsik Gy.: Effect of acute (ASV) and chronic (CSV) surgical vagotomy on the vascular permeability of the gastric mucosa after 96% ethanol (ETOH) treatment in rats. Acta Physiol. Hung. 1992; 80: 221-226.

39.    Király Á., Matus Z., Sütő G., Vincze Á., Mózsik Gy.: Correlation between the β-carotene induced gastric cytoprotective effect and its gastric mucosal level in indomethacin-treated rats. Acta Physol. Hung. 1992; 80: 215-220.

40.    Sütő G., Király Á., Vincze Á., Jávor T., Mózsik Gy.: Effect of acute surgical vagotomy (ASV) on the mucosal content of 6-keto-PGF1α, PGE2 and glutathione (GSH) after intragastric 96% ethanol (ETOH) treatment in rats. Acta Physiol. Hung. 1992; 80: 207-213.

41.    Foldes K, Gaal M, Balint P, Nemenyi K, Kiss C, Balint GP, Buchanan WW Ultrasonography after hip arthroplasty. Skeletal Radiol 1992; 21: 297-299.
42.    Molnár I, Balázs C, Szabó E, Czirják L. Evaluation of thyroid function and anti-thyroid autoantibodies in systemic sclerosis. Acta Dermato-Venereol (Stockh.) 1992; 72: 112-115.

43.    Molnár I, Balázs C, Szabó E, Czirják L. Anti-thyroid antibodies and hypothyroidism in systemic sclerosis. J Endocrinol Invest 1992; 15: 311.

44.    Czirjak L., Szolnoki E., Nagy Z., Szegedi G. Changes in pulmonary function in systemic sclerosis [letter] Postgrad Med J. 1992; 68: 388.

45.    Czirják L, Nagy Z., Szegedi Gy.  Systemic sclerosis in the elderly. Clin Rheumatol 1992; 11: 483-485.

46.    Mózsik Gy., Karádi O., Király Á., Matus Z., Sütő G., Tóth Gy., Vincze, Á.: Vagal nerve and the gastric mucosal defense. J. Physiol.(Paris) 1993; 87: 329 334.

47.    Vincze Á., Király Á., Sütő G., Mózsik Gy.: Changes of gastric mucosal biochemistry in ethanol treated rats with and without acute surgical vagotomy. J. Physiol.(Paris) 1993; 87: 339 341.

48.    Vincze Á., Garamszegi M., Karádi O., Király Á., Nagy L., Sütő G., Tóth Gy., Mózsik Gy.: Cellular energy status of the gastric mucosa and gastric mucosal damage prevention by vitamin A in indomethacin treated rats. Exp. Clin. Gastroenterol. 1993; 3: 199-205.

49.    Mózsik Gy., Garamszegi M., Karádi O., Király Á., Nagy L., Sütő G., Vincze Á.: Correlation between the gastric mucosal biochemistry, vascular permeability and mucosal protection produced by cytoprotective and antisecretory doses  of atropine and cimetidine in rats treated with indomethacin. Exp. Clin. Gastroenterol. 1993; 3: 205-215.

50.    Király Á., Sütő G., Taché Y.: Role of nitric oxide in the gastric cytoprotection induced by central vagal stimulation. Eur. J. Pharmacol. 1993; 240: 299-301.

51.    Czirják L, Schlammadinger J, Szegedi Gy. Systemic sclerosis and exposure to trichloroethylene. Dermatology 1993; 186: 236.

52.    Hegedüs I, Czirják L. Left ventricular wall thickness and disease duration in systemic sclerosis Postgrad Med J 1993; 69: 291-295.

53.    Seres T, Nagy Z., Czirják L. Investigation of basophil cell proteinase release in progressive systemic sclerosis. Allergy 1993; 48: 164-167.

54.    Czirják L, Zeher M, Nagy Z., Szegedi Gy. Sjögren`s syndrome, primary biliary cirrhosis and overlap with scleroderma symptoms. J Int Med 1993; 233: 427-428.

55.    Czirják L, Nagy Z. and Szegedi Gy. Survival analysis of 118 patients with systemic sclerosis. J Int Med 1993; 234: 335-37.

56.    Koó É., Nagy Z., Seszták M., Merétey K., Böhm U., Forgács S., Szilágyi M., Farkas V., Czirják L. Cluster analysissel nyert arthritis psoriatica alcsoportok. Magyar Reumatológia 1993; 34: 325-33.

57.    Karádi O., Bódis B., Király Á., Abdel-Salam O.M.E., Sütő G., Vincze Á., Mózsik Gy.: Surgical vagotomy enhances the indomethacin-induced gastrointestinal mucosal damage in rats. Inflammopharmacology 1994; 2: 389-399.

58.    Plourde V., Quintero E., Sütő G., Coimbra C., Taché Y.: Delayed gastric emptying induced by inhibitiors of nitric oxide synthase in rats. Eur. J. Pharmacol. 1994; 256: 125-129. 

59.    Taché Y., Yoneda M., Kato K., Király Á., Sütő G., Kaneko H.: Intracisternal thyrotropin-releasing hormone-induced vagally mediated gastric protection against ethanol lesions: Central and peripheral mechanisms. J. Gastroenterol. Hepatol. 1994; 9: S29-S35.

60.    Király Á., Sütő G., Livingston EH., Guth PH., St.Pierre S., Taché Y.: Central vagal activation by TRH induces gastric hyperemia: Role of CGRP in capsaicin-sensitive afferents in rats. Am. J. Physiol. (Gastrointestinal and Liver Physiol.) 1994; 267: G1041-G1049.

61.    Sütő G., Király Á., Taché Y.: Interleukin-1β inhibits gastric emptying in rats. Mediation through prostaglandin and corticotropin-relasing factor. Gastroenterology 1994; 106: 1568-1775.

62.    Nagy G, Kovács J, Zeher M. and Czirják L. Analysis of the oral manifestations in systemic sclerosis. Oral Surg Oral Med Oral Pathol 1994; 77: 141-46.

63.    Czirják L, Pócs E, Szegedi Gy. Localized scleroderma after exposure to organic solvents. Dermatology 1994; 189: 399-401.

64.    Czirják L, Molnár I, Csipô I, Szabolcs M, Mihály A, Szegedi G. Anti platelet antibodies against gpIIb/IIIa in systemic sclerosis. Clin Exp Rheumatol 1994; 12: 527-529.

65.    Hegedüs I, Czirják L. Left ventricular wall motion in 80 patients with systemic sclerosis. Clin Rheumatol 1995; 14: 161-164.

66.    Csipô I, Czirják L, Szántó S, Szerafin L, Sipka S, Szegedi G. Decreased serum tryptophan and elevated neopterin levels in systemic sclerosis. Clin Exp Rheumatol 1995; 13: 269-270.

67.    Dévényi K,  Czirják L. High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma Clin Rheumatol 1995; 14: 633-640.

68.    Gaál J, Hegedüs I, Dévényi K, Czirják L. Myocardium gallium-67 citrate scintigraphy in 16 patients with systemic sclerosis. Ann Rheum Dis 1995; 54: 856-858.

69.    Czirják L, Csiki Z, Nagy Z, and Tóth E. Exposure to chemicals and systemic sclerosis (comment). Ann Rheum Dis  1995; 54: 529.

70.    Sütő G., Király Á., Plourde V., Taché Y.: Intravenous interleukin-1β-induced inhibition of gastric emptying: involvement of central corticotropin-releasing factor and prostaglandin pathways in rats. Digestion 1996; 57: 135-140.

71.    Szegedi A, Czirják L, Unkeless, JC, Boros P. Detection of serum cytokine levels in 18 patients with systemic sclerosis. Acta Dermato-Venereol (Stockh.) 1996; 76: 21-23.

72.    Szegedi A, Czirják L. Detection of anti Fc gamma antibodies and different cytokines in sera from  patients with systemic sclerosis. J Am Acad Dermatol 1996; 35: 134.

73.    Czirják L, Nagy Z, Csiki Z. Primary biliary cirrhosis and other gastrointestinal symptoms in 76 patients with systemic sclerosis. Il Friuli Medico. Alp Adria Journal of Medicine. (special issue). 1996. 1:38-42.

74.    Szeberenyi J, Boglari G, Komaromy L, Nusser N, Pap M, Sebok A, Setalo G Jr, Tigyi A. Problem-oriented teaching of molecular cell biology. Med. Educ. 1996; 30: 232-4.

75.    Király Á, Sütő G., Guth P.H., Taché Y.: Mechanisms mediating gastric hyperemic and acid responses to central TRH analog at a cytoprotective dose. Am. J. Physiol. (Gastrointestinal and Liver Physiol.) 1997; 273: G31-G38.

76.    Király Á, Rivier J., Sütő G., Taché Y.: VIP and central TRH-induced gastric vasodilation: influence of [4Cl-D-Phe6,Leu17]VIP antagonist. Peptides 1997; 18(9): 1321-1325.

77.    Király Á, Sütő G., Guth P.H., Taché Y.: Ketotifen prevents gastric hyperemia induced by intracisternal thyrotropin-releasing hormone at a low dose. Eur. J. Pharmacol. 1997; 334: 241-247.

78.    Nagy Z., Czirják L. Predictors of Survival in 171 Patients with Systemic Sclerosis (Scleroderma). Clin Rheumatol  1997; 16: 454-460.

79.    Király Á., Sütő G., Guth P.H., Taché Y.: Peripheral mediators involved in the gastric hyperemic response to vagal activation by central TRH in rats. Am. J. Physiol. (Gastrointestinal and Liver Physiol.) 1998; 274: G170-G177.

80.    Berki T., Kumánovics G., Kumánovics A., Falus A., Újhelyi E., Németh P.: Production and flow cytometric application of a monoclonal anti-glucocorticoid receptor antibodydy. J. of Immun. Methods 1998; 214:19-27.

81.    Fischer DJ, Liliom K, Guo Z, Nusser N, Virag T, Murakami-Murofushi K, Kobayashi S, Erickson JR, Sun G, Miller DD, Tigyi G. Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes. Mol. Pharmacol. 1998; 54: 979-88.

82.    Nagy Zs., Nagy Á., Karádi O., Figler M., Sütő G., Vincze Á., Pár A., Mózsik Gy.: Leiden mutation in patient with Crohn�s disease. Inflammopharmacology 1999; 7: 297-301.

83.    Mózsik Gy., Rumi Gy., Bódis B., Figler M., Király Á., Sütő G., Vincze Á.: Effects of indomethacin, with vitamin A or -carotene, on the rat gastric mucosa: Extra- and intracellular membrane-bound ATP mechanisms. Infalmmopharmacology 1999; 7: 287-295.

84.    Fábián G, Tóvári E, Baranyay F, Czirják L.: Watermelon-stomach as a cause of chronic iron deficiency anemia in a patient with systemic sclerosis. J Eur Acad Dermatol Venereol  1999; 12: 161-164.

85.    Czirják L., Koncz A., Varga I., Dévényi K., Kumánovics G., Szűcs G.: Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis. Clin Rheumatol 1999;18(5):357-63.

86.    Sebok A, Nusser N, Debreceni B, Guo Z, Santos MF, Szeberenyi J, Tigyi G.  Different roles for RhoA during neurite initiation, elongation, and regeneration in PC12 cells. J. Neurochem. 1999; 73: 949-60.

87.    Sütő G., Vincze Á., Pakodi F., Hunyady B., Karádi O., Garamszegi M., László T., Mózsik Gy.: 13C-urea breath test is superior in sensitivity to detect Helicobacter pylori infection than either antral histology or rapid urease test. J.  Physiol. (Paris) 2000; 94: 153-156.

88.    Király Á., Sütő G., Tam B., Hermann V., Mózsik Gy.: Vagus-mediated action of ketitofen on gastric mucosal lesion formation and acid secretion induced by a high dose of intracisternal TRH analogue.  J. Physiol. (Paris)  2000; 94: 131-134.

89.    Tigyi G, Fischer DJ, Baker D, Wang DA, Yue J, Nusser N, Virag T, Zsiros V, Liliom K, Miller D, Parrill A. Pharmacological characterization of phospholipid growth-factor receptors. Ann. N.Y. Acad. Sci. 2000; 905: 34-53.

90.    Liliom K, Bunemann M, Sun G, Miller D, Desiderio DM, Brandts B, Bender K, Pott L, Nusser N, Tigyi G. Sphingosylphosphorylcholine is a bona fide mediator regulating heart rate. Ann. N.Y. Acad. Sci. 2000; 905: 308-10.

91.    Moosig F., Csernok E., Kumánovics G., Gross W.L.: Opsonisation of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-a). Clin Exp Immunol 2000; 122: 499-503.

92.    Komócsi A, Tóvári E, Kovács J, Czirják L.: Physical injury as provoking factor in three patients with scleroderma. Clin Exp Rheumatol 2000; 18: 622-624.

93.    Molnár I, Czirják L.: Inhibitory effect of sera on the thyroid 5�- deiodinase activity in systemic sclerosis. Clin Exp Rheumatol 2000; 18: 719-724.

94.    Mózsik Gy., Bódsi B., Figler M., Király Á., Karádi O., Pár. A., Rumi Gy., Sütő G., Tóth Gy., Vincze Á.: Mechanisms of action of retinoids in gastrointestinal mucosal protection in animals, human healthy subjects and patientes. Life Sciences 2001; 69: 3103-3112.

95.    Vincze Á., Karádi O., Hunyady B., Pakodi F., Sütő G., Mózsik Gy.: One year follow up of patients after succesful helicobacter pylori eradication therapy. J. Physiol (Paris). 2001; 95: 457-460.

96.    Nagy Zs., Nagy Á., Karádi O., Figler M., Rumi Gy. jr., Sütő G., Vincze Á., Pár A., Mózsik Gy.: Prevalence of factor V Leiden mutation in human inflammatory bowel disease with different activity. J. Physiol (Paris). 2001; 95: 483-487.

97.    Király Á., Sütő G., Czimmer J., Horváth Ö. P., Mózsik Gy.: Failure of capsaicin-containing red pepper sauce suspension to induce esophageal motility response in patients with Baretts esophageus. J. Physiol. (Paris) 2001; 95: 197-201.

98.    Mózsik Gy., Karádi O., Király Á., Debreceni A., Figler M., Nagy L., Pár A., Pár G., Sütő G., Vincze Á.: The key-role of vagal nerve and adrenals in the cytoprotection and general gastric mucosal intergity. J. .Physiol (Paris) 2001; 95: 229-239.

99.    Liliom K, Sun G, Bunemann M, Virag T, Nusser N, Baker DL, Wang DA, Fabian MJ, Brandts B, Bender K, Eickel A, Malik KU, Miller DD, Desiderio DM, Tigyi G, Pott L. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem. J. 2001; 355: 189-97.

100.    Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang Da, Baker DL, Bautista D, Parrill AL, Tigyi G. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 2001; 60: 776-84.

101.    Koó É, Nagy Z, Seszták M, Ujfalussy I, Merétey K, Böhm U, Forgács S, Szilágyi M, Czirják L, Farkas V. Subsets in psoriatic arthritis formed by cluster analysis. Clin Rheumatol 2001 ; 20: 36-43.

102.    Komócsi A., Kumánovics G., Zibotics H., Czirják L.: Alveolitis may persist during the immunsuppressive treatment sufficiently controlling the inflammatory muscle disease in patients with myositis. Rheumatol Int 2001; 20: 113-8.

103.    Kumánovics G., Zibotics H., Juhász E., Komócsi A., Czirják L.: Subclinical pulmonary involvement assessed by bronchoalveolar lavage in patients with undifferentiated connective tissue disease. Clin Exp Rheumatol 2001; 19: 551-559.

104.    Horváth L, Czirják L, Fekete B, Jakab L, Prohászka Z, Cervenák L, Romics L, Singh M, Daha MR, Füst G.: Levels of antibodies against C1q and 60 kDa family of  heat shock proteins in the sera of patients with various  autoimmune diseases. Immunol Let  2001; 75: 103-109.

105.    Koó É, Nagy Z, Seszták M, Ujfalussy I, Merétey K, Böhm U, Forgács S, Szilágyi M, Czirják L, Farkas V. Subsets in psoriatic arthritis formed by cluster analysis. Clin Rheumatol 2001 ; 20: 36-43.

106.    I�tok R, Czirják L, Stančíková M, Lukáč J, Rovenský J.: Pyridinoline cross-link compounds of collagen in systemic sclerosis and Raynaud�s phenomenon. Rheumatology (Oxford) 2001; 40:140-146.

107.    Komócsi A, Kumánovics G, Zibotics H, Czirják L.: Signs of alveolitis may persist during the immunsuppressive treatment sufficiently controlling the inflammatory muscle disease in patients with myositis. Rheumatol Int 2001; 20: 113-118.

108.    Della Rossa A, Valentini G, Bombardieri S, Bencivelli W, Silman AJ, Cerinic MM, Belch JJ, Black CM, Becvar R, Bruhlman P, Cozzi F, Czirják L, et al.: European multi-centre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 318 patients from 19 centres. Ann Rheum Dis 2001; 60: 585-591.

109.    Valentini G,, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, Cerinic MM, Belch JJ, Black CM, Becvar R, Bruhlman P, Cozzi F, Czirják L, et al.: European multi-centre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-598.

110.    Illei, GG, Czirják, L. Novel approaches to the treatment of lupus nephritis. Expert Opinion on Invetigational Drugs 2001 ; 10: 1117-1130.

111.    Komócsi A, Tóvári E, Pajor L, Czirják L.: Histiocytic necrotising lymphadenitis preceding systemic lupus erythematosus.J Eur Acad Dermatol Venereol 2001; 15: 476-480.

112.    Horváth L, Czirják L, Fekete B, Jakab L, Pozsonyi T, Kalabay L, Romics L, Miklós K, Varga L, Prohászka Z, Szakács A, Nagy E, Daha MR, Füst G. High levels of antibodies against C1q are associated with the disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001; 19: 667-672.

113.    Szigeti, N, Fábián Gy, Czirják L. Fatal scleroderma renal crisis caused by gastrointestinal bleeding in a patient with scleroderma, Sjogren`s syndrome and primary biliary cirrhosis overlap. J Eur Acad Dermatol Venereol 2001; 16:276-279.

114.    Sardar VM, Bautista DL, Fischer DJ, Yokoyama K, Nusser N, Virag T, Wang DA, Baker DL, Tigyi G, Parrill AL. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim. Biophys. Acta. 2002; 1582: 309-17.

115.    Nusser N, Gosmanova E, Zheng Y, Tigyi G. Nerve growth factor signals through TrkA, phosphatidylinositol 3-kinase, and Rac1 to inactivate RhoA during the initiation of neuronal differentiation of PC12 cells. J. Biol. Chem. 2002; 277: 35840-6.

116.    Czirják L., Kumánovics G.: Exposure to solvents in female patients with scleroderma. Clin Rheumatol 2002; 21(2):114-8.

117.    Tóvári, E, Mezey, I, Berencsi, G, Czirják, L. Lupus-like symptoms in three patients with parvovirus B 19 infection (letter). Ann Rheum Dis 2002; 61: 662-663.

118.    Lamprecht P., Kumánovics G., Mueller A, Csernok E, Komócsi A, Trabandt A, Gross WL, Schnabel A.: Elevated monocytic IL-12 and TNF-alpha production in Wegener`s granulomatosis is normalized by cyclophosphamide and corticosteroid therapy.
Clin Exp Immunol. 2002; 128(1):181-6.

119.    Kalabay L, Fekete B, Czirjak L, Horvath L, Daha MR, Veres A, Fonyad G, Horvath A, Viczian A, Singh M, Hoffer I, Fust G, Romics L, Prohaszka Z. Helicobacter pylori infection in connective tissue disorders is associated with high levels of antibodies to mycobacterial hsp65 but not to human hsp60. Helicobacter 2002 7:250-256.

120.    Tóvári, E, Mezey, I, Berencsi, G, Czirják, L. Lupus-like symptoms in three patients with parvovirus B 19 infection (letter). Ann Rheum Dis 2002; 61: 662-663.

121.    Kumánovics G., Magyarlaki T., Komócsi A., Szekeres Gy., Czirják L.: Simultaneous presence of neutrophil alveolitis and Ki-67 positivity of alveolar macrophages in dermato/polymyositis and systemic sclerosis. Rheumatology (nyomdában).

122.    Valentini, G, Bencivelli, W, Bombardieri, S, D`Angelo, S, Della Rossa, A, Silman, AJ, Black, CM, Czirják,L, Nielsen, H, Vlachoyiannopoulos, PG: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis (submitted).

123.    Nagy Z, Czirják L.: Nailfold digital capillaroscopy in 447 patients connective tissue diseases and Raynaud`s phenomenon. J Eur Acad Dermatol Venereol (submitted)

124.    Czirják L, Nagy Z. Increased C reactive protein level is a predictors of survival in patients with systemic sclerosis (scleroderma) Clin Rheumatol (submitted)

125.    Varjú C, Pethő E, Kutas R, Czirják L: The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis Clinical Rehabilitation (elfogadva, közlés alatt)

126.    Szigeti, N, Fábián Gy, Czirják L. Fatal scleroderma renal crisis caused by bleeding of gastrointestinal teleangiectasia in a patient with scleroderma, Sjögren`s syndrome, and primary biliary cirrhosis overlap. J Eur Acad Dermatol Venereol